Phase 1 biotech developing allogeneic NK T cells for cancer and other diseases.
Industry: Health Care
Latest Trade: $0.68 -0.02 (-3.0%)
First Day Return: 0.0%
Return from IPO: -94.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/14/2021 |
Offer Price | $12.00 |
Price Range $12.00 - $14.00 | |
Offer Shares (mm) | 3.3 |
Deal Size ($mm) | $40 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 10/14/2021 |
Offer Price | $12.00 |
Price Range $12.00 - $14.00 | |
Offer Shares (mm) | 3.3 |
Deal Size ($mm) | $40 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Evercore ISI |
William Blair |
more |
Company Data | |
---|---|
Headquarters | New York, NY, United States |
Founded | 2017 |
Employees at IPO | 34 |
Website www.minktherapeutics.com |